Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) hit a new 52-week low during mid-day trading on Thursday. The company traded as low as $31.63 and last traded at $31.63, with a volume of 200 shares changing hands. The stock had previously closed at $35.50.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the company. Barclays downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Finally, Zacks Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold”.
Get Our Latest Stock Report on Zealand Pharma A/S
Zealand Pharma A/S Trading Down 10.4%
The business’s 50 day simple moving average is $37.72 and its 200 day simple moving average is $46.02. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of 4.67 and a beta of 0.99.
Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($1.57) by $1.45. Zealand Pharma A/S had a net margin of 67.13% and a return on equity of 19.70%. The business had revenue of $0.62 million during the quarter, compared to the consensus estimate of $1.33 million. Research analysts anticipate that Zealand Pharma A/S will post 5.35 EPS for the current year.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.
Featured Articles
- Five stocks we like better than Zealand Pharma A/S
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
